Stargardt disease is an inherited macular dystrophy that typically causes progressive central vision loss while peripheral vision remains relatively preserved.
Prognosis
The rate of decline varies with the underlying genetic mutation and age of onset.
- Many patients reach legal driving thresholds in adolescence or early adulthood, though some progress more slowly.
- Peripheral fields and mobility are usually maintained, allowing good orientation in familiar environments.
- There is currently no widely available cure, but several gene and pharmacologic therapies are under investigation.
- UV and blue‑light protection and avoidance of smoking are generally recommended.
Management
Care focuses on maximising remaining vision and supporting independence.
- Low‑vision aids, electronic magnifiers, and adaptive technology can greatly enhance reading and education.
- Regular monitoring with OCT and fundus imaging tracks structural change and helps identify eligibility for clinical trials.
- Genetic counselling informs family planning and access to emerging therapies.
- Registration with sight‑loss services can provide practical and psychological support.
